MultiPlan (MPLN) Stock Price, News & Analysis

Company Overview

MultiPlan Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. MultiPlan Corporation was founded in 1980 and is headquartered in New York, New York.

Key Stats

• Today's Range: $28.01 to $29.48
• 50-Day Range: $6.02 to $29.46
• 52-Week Range: $4.80 to $48.80
• Volume: 173,187 shs
• Average Volume: 165,208 shs
• Market Capitalization: $474.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.25
• Consensus Rating: Hold

MultiPlan Stock Analysis - MarketRank™

MultiPlan scored higher than 17% of companies evaluated by MarketBeat, and ranked 889th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

MultiPlan has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

MultiPlan has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MultiPlan are expected to decrease in the coming year, from ($6.84) to ($8.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MultiPlan is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MultiPlan is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MultiPlan has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.32% of the float of MultiPlan has been sold short.

Short Interest Ratio / Days to Cover

MultiPlan has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MultiPlan has recently decreased by 2.60%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MultiPlan does not currently pay a dividend.

Dividend Growth

MultiPlan does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.32% of the float of MultiPlan has been sold short.

Short Interest Ratio / Days to Cover

MultiPlan has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MultiPlan has recently decreased by 2.60%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.41

News Sentiment

MultiPlan has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for MultiPlan this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for MPLN on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MultiPlan insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.00% of the stock of MultiPlan is held by insiders.

Percentage Held by Institutions

87.15% of the stock of MultiPlan is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MPLN Stock Analysis - Frequently Asked Questions

How have MPLN shares performed this year?

MultiPlan's stock was trading at $14.78 at the beginning of the year. Since then, MPLN shares have increased by 98.4% and is now trading at $29.3230.
View the best growth stocks for 2025 here.

How were MultiPlan's earnings last quarter?

MultiPlan Co. (NYSE:MPLN) posted its earnings results on Thursday, August, 1st. The company reported ($1.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.60) by $0.40. The company had revenue of $233.48 million for the quarter, compared to the consensus estimate of $253.59 million. MultiPlan had a negative trailing twelve-month return on equity of 12.14% and a negative net margin of 163.30%.

When did MultiPlan's stock split?

MultiPlan shares reverse split on Monday, September 23rd 2024. The 1-40 reverse split was announced on Tuesday, September 10th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are MultiPlan's major shareholders?

MultiPlan's top institutional shareholders include Ares Management LLC (5.53%), Beach Point Capital Management LP (2.38%), Topline Capital Management LLC (1.99%) and CastleKnight Management LP (1.39%). Insiders that own company stock include Travis Dalton, Douglas Michael Garis, William B Mintz, Mark Tabak, Michael Kim and Anthony Colaluca Jr.
View institutional ownership trends.

How do I buy shares of MultiPlan?

Shares of MPLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MultiPlan own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MultiPlan investors own include Organigram (OGI), Ford Motor (F), NVIDIA (NVDA), Lucid Group (LCID), ChargePoint (CHPT) and i3 Verticals (IIIV).

Company Calendar

• Last Earnings: 8/01/2024
• Today: 2/21/2025
• Next Earnings (Confirmed): 2/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Business services, not elsewhere classified
• Sub-Industry: Business Services
• Current Symbol: NYSE:MPLN
• CUSIP: N/A
• CIK: 1793229
• Web: www.multiplan.us
• Phone: 212-780-2000
• Fax: N/A
• Employees: 2,800
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $26.25
• High Stock Price Target: $40.00
• Low Stock Price Target: $12.50
• Potential Upside/Downside: -10.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($95.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-91,700,000.00
• Net Margins: -163.30%
• Pretax Margin: -171.48%
• Return on Equity: -12.14%
• Return on Assets: -1.84%

Debt

• Debt-to-Equity Ratio: 21.73
• Current Ratio: 1.05
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: $961.52 million
• Price / Sales: 0.49
• Cash Flow: $17.88 per share
• Price / Cash Flow: 1.64
• Book Value: $105.45 per share
• Price / Book: 0.28

Miscellaneous

• Outstanding Shares: 16,170,000
• Free Float: 14,877,000
• Market Cap: $474.15 million
• Optionable: Optionable
• Beta: 0.13